PubMed:32513289 / 0-214 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":4,"end":14},"obj":"SP_7"},{"id":"T2","span":{"begin":107,"end":115},"obj":"SP_7"},{"id":"T3","span":{"begin":153,"end":161},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset:"}

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":214},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":214},"obj":"Sentence"}],"text":"The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset:"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":4,"end":12},"obj":"Disease"},{"id":"T2","span":{"begin":107,"end":115},"obj":"Disease"},{"id":"T3","span":{"begin":153,"end":161},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset:"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":184,"end":186},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"}],"text":"The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset:"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":214},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset:"}